The CEPHEUS study demonstrated that transplantineligible or transplant-deferred patients with newly diagnosed multiple myeloma (NDMM) treated with daratumumab, bortezomib, lenalidomide and dexamethasone (D-VRd) had higher rates of overall minimal residual disease (MRD)-negativity than those who received bortezomib, lenalidomide and dexamethasone (VRd). The aim of the present paper was to provide an expanded analysis of MRD from the CEPHEUS study.

Renal impairment is a serious complication of newly diagnosed multiple myeloma (NDMM) that considerably reduces overall survival, and rapid renal recovery is therefore an important treatment goal. Because lenalidomide is renally excreted, current guidelines recommend that patients with transplanteligible NDMM and renal impairment should receive a reduced dose of lenalidomide induction therapy (5–10 mg/day), but studies have challenged the need for such cautious dosing. The aim of this analysis was to evaluate the efficacy and safety of higher-dose lenalidomide induction therapy in transplant-eligible patients with NDMM and renal impairment.

The combination of teclistamab (a bispecific antibody targeting B-cell maturation antigen and CD3) and daratumumab has been shown to have strong efficacy as early as first relapse among patients with relapsed or refractory multiple myeloma. The aim of this study was to evaluate the safety and efficacy of teclistamab- based regimens in patients with newly diagnosed multiple myeloma (NDMM).

Patients with relapsed or refractory multiple myeloma (RRMM) usually receive bispecific antibody (BsAb) therapy indefinitely until disease progression or intolerable side effects, but some patients have been reported to have sustained remission after just a limited duration of BsAb therapy. The aim of this study was to report on sustained remission, immune reconstitution and infection risk off-treatment in a larger cohort of patients with RRMM treated with a finite duration of BsAb therapy.